Panacea Acquisition's equity warrant, NUVB.WS, has seen its price target downgraded by analysts from $0.16 to $0.04, marking a 72.02% decline. Despite a current price of $0.03 suggesting 51.60% upside, institutional investors displayed mixed sentiment, with a slight decrease in participants but an increase in holdings. Major funds maintained their positions, indicating stable conviction.